Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-124712
Filing Date
2024-11-12
Accepted
2024-11-12 09:08:08
Documents
53
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cogt-20240930.htm   iXBRL 10-Q 1651071
2 EX-31.1 cogt-ex31_1.htm EX-31.1 13147
3 EX-31.2 cogt-ex31_2.htm EX-31.2 13135
4 EX-32.1 cogt-ex32_1.htm EX-32.1 8420
5 EX-32.2 cogt-ex32_2.htm EX-32.2 8395
6 GRAPHIC img158370842_0.jpg GRAPHIC 82098
  Complete submission text file 0000950170-24-124712.txt   6331300

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cogt-20240930.xsd EX-101.SCH 836463
55 EXTRACTED XBRL INSTANCE DOCUMENT cogt-20240930_htm.xml XML 934001
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

EIN.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38443 | Film No.: 241444004
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)